
Deep Apple Therapeutics discovers novel small-molecule drug candidates for validated targets in inflammatory, metabolic, and endocrine diseases. The company combines ensemble cryo-EM to map receptor conformations with deep learning and large-scale molecular docking of multi‑billion compound libraries generated by its proprietary Orchard.ai algorithm. Its platform is a structure-based, machine-learning driven drug discovery engine built on computational modeling, protein structure determination, and analysis of protein dynamics to prioritize candidates rapidly. Deep Apple operates as a biotech drug discovery company targeting partnerships and preclinical advancement of novel small molecules.

Deep Apple Therapeutics discovers novel small-molecule drug candidates for validated targets in inflammatory, metabolic, and endocrine diseases. The company combines ensemble cryo-EM to map receptor conformations with deep learning and large-scale molecular docking of multi‑billion compound libraries generated by its proprietary Orchard.ai algorithm. Its platform is a structure-based, machine-learning driven drug discovery engine built on computational modeling, protein structure determination, and analysis of protein dynamics to prioritize candidates rapidly. Deep Apple operates as a biotech drug discovery company targeting partnerships and preclinical advancement of novel small molecules.
Founded: 2022
HQ / Base: San Francisco
Focus: Small-molecule drug discovery (GPCRs, membrane proteins); inflammatory, metabolic, endocrine diseases
Platform: Ensemble cryo-EM, deep learning, molecular dynamics, ultra-large virtual-library docking (Orchard.ai)
Series A: $52M (Dec 14, 2023) led by Apple Tree Partners
Drug discovery for inflammatory, metabolic, and endocrine diseases, with emphasis on GPCR and membrane-protein targets.
2022
Biotechnology Research
$52,000,000
Company created and incubated by Apple Tree Partners; Series A announced upon emergence from stealth.
“Led and incubated by Apple Tree Partners”
| Company |
|---|